23510-98-7

Basic information

• Product Name: 4-(Methylthio)cyclohexanone
• Synonyms: 4-(Methylthio)cyclohexanone;4-(Methylsulfanyl)cyclohexan-1-one;4-(methylthio)cyclohexan-1-one
• CAS NO: 23510-98-7
• Molecular Formula: C₇H₁₂OS
• Molecular Weight: 144.23
• Mol File: 23510-98-7.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 241.4±33.0 °C(Predicted)
• Appearance: /
• Density: 1.04±0.1 g/cm3(Predicted)
• CAS DataBase Reference: 4-(Methylthio)cyclohexanone(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(Methylthio)cyclohexanone(23510-98-7)
• EPA Substance Registry System: 4-(Methylthio)cyclohexanone(23510-98-7)

Safety Data

• Hazardous Substances Data: 23510-98-7(Hazardous Substances Data)

Upstream product

• 55103-51-0 8-(methylthio)-1,4-dioxaspiro[4.5]decane 
• 104-15-4 toluene-4-sulfonic acid 
• 22428-87-1 4,4-ethylenedioxycyclohexan-1-ol 
• 141120-33-4 8-methylsulfonyloxy-1,4-dioxaspiro[4.5]decane 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 23511-05-9 toluene-4-sulfonic acid 1,4-dioxa-spiro[4.5]dec-8-yl ester 
• 74-93-1 methylthiol 

Downstream Products

• 862129-72-4 4-(methylsulfonyl)cyclohexan-1-one 

Relevant articles and documents

PYRIDINYL PYRAZOLES AS MODULATORS OF RORyT

The present invention comprises compounds of Formula I. wherein: R1, R3, R4, R5, R6, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-γ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

PHENYL AND PYRIDINYL SUBSTITUTED IMIDAZOLES AS MODULATORS OF RORyT

The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, Ra, Rb, Q1, and Q2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-γ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS

The invention relates to novel compounds and also to methods of treating at least one disease, disorder, or condition associated with amyloidosis using such compounds. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.